期刊文献+

HPV58 E2 DNA疫苗的构建及免疫原性研究

Construction and immunogenic evaluation of a DNA vaccine containing the human papillomavirus type 58 E2 gene
原文传递
导出
摘要 目的探讨人乳头瘤病毒58型(HPV58)早期基因E2作为DNA疫苗候选抗原的可行性。方法构建HPV58E2真核重组表达载体pcDNA3/58E2,转染SiHa细胞,利用RT-PCR检测HPV58E2mRNA的转录。pcDNA3/58E2DNA肌肉注射免疫BALB/C小鼠,ELISA检测小鼠血清中特异性anti-HPV58E2IgG水平。结果RT-PCR结果表明,pcD-NA3/58E2能够在真核细胞中有效转录HPV58E2mRNA。动物实验表明,质粒pcDNA3/58E2肌肉接种可诱导免疫小鼠产生抗E2特异性抗体。结论本研究成功构建了重组真核表达载体pcDNA3/58E2,并初步证明HPV58E2DNA疫苗有良好的免疫原性。 Objective Uo study the possibility of the human papillomavirus type 58 early gene E2 as a candidate antigen of DNA vaccine.Methods Recombinant eukaryotic vector pcDNA3/58E2 was constructed and was transfected into SiHa cells.HPV58 E2 mRNA transcripts were examined by RT-PCR.BALB/C mice were immunized by muscle injection with plasmid pcDNA3/58E2,and serum specific anti-HPV58E2 IgG was detected by ELISA.Results HPV58 E2 mRNA transcripts were detectable in SiHa cells by RT-PCR,and specific anti-HPV58E2 IgG could be induced in mice immunized with plasmid pcDNA3/58E2.Conclusion The recombinant plasmid pcDNA3/58 E2 was successfully constructed,and it could stimulate an E2 specific immune response in mice as a DNA vaccine.
出处 《山东大学学报(医学版)》 CAS 北大核心 2009年第12期17-20,共4页 Journal of Shandong University:Health Sciences
基金 国家自然科学基金资助项目(30470086)
关键词 人类乳头瘤病毒58型(HPV58) E2基因 DNA疫苗 宫颈癌 Human papillomavirus type 58(HPV58) Gene E2 DNA vaccine Cervical cancer
  • 相关文献

参考文献10

  • 1Szarka K, Tar I, Feher E, et al. Progressive increase of human papillomavirus carriage rates in potentially malignant and malignant oral disorders with increasing malignant potential[J]. Oral Microbiol Immunol, 2009, 24(4) :314-318.
  • 2Qiu A D, Wu E Q, Yu X H, et al. HPV prevalence, E6 sequence variation and physical state of HPV16 isolates from patients with cervical cancer in Sichuan, China[J]. Gynecol Oncol, 2007, 104(1) :77-85.
  • 3Liaw K L, Hsing A W, Schiffman M H, et al. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women[J]. Int J Cancer. 1997. 73(5) :775-776.
  • 4Hsueh P R. Human papillomavirus, genital warts, and vaccines[J]. J Microbiol Immunol Infect, 2009, 42(2) :101-106.
  • 5van Poelgeest M I, Nijhuis E R, Kwappenberg K M, et al. Distinct regulation and impact of type 1 T-cell immunity against HPVI6 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia[J]. Int J Cancer, 2006, 118(3) :675-683.
  • 6Roden R B, Ling M, Wu T C. Vaccination to prevent and treat cervical cancer[J]. Hum Pathol, 2004, 35(8) :971-982.
  • 7Garcia-Hernandez E, Gonzalez-Sanchez J L, Andrade-Manzano A, et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine [ J ]. Cancer Gene Ther, 2006, 13 (6) :592-597.
  • 8Heinemann L, Woodfield L, Amer M, et al. Effective induction of type 1 helper IgG2a and cytotoxic T-cell responses in mice following immunization with human papillomavirus type 16 E2 in MF59[J]. Viral Immunol, 2008, 21(2) :225-233.
  • 9王立良,肖长义.乳头瘤病毒E2蛋白的分子生物学研究进展[J].国外医学(分子生物学分册),1999,21(6):325-333. 被引量:1
  • 10Hung C F, Monie A, Alvarez R D, et al. DNA vaccines for cervical cancer: from bench to bedside[J]. Exp Mol Med, 2007, 39(6) :679-689.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部